eidd Search Results


eidd 1931  (MedChemExpress)
95
MedChemExpress eidd 1931
Eidd 1931, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/eidd/EIDD-1931/pm39306285-58-8-13
Average 95 stars, based on 1 article reviews
eidd 1931 - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
n 4 hydroxycytidine  (Selleck Chemicals)
93
Selleck Chemicals n 4 hydroxycytidine
N 4 Hydroxycytidine, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/eidd/EIDD-1931/pmc12548437-48-15-19
Average 93 stars, based on 1 article reviews
n 4 hydroxycytidine - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
molnupiravir mpv  (MedChemExpress)
95
MedChemExpress molnupiravir mpv
Molnupiravir Mpv, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/eidd/Molnupiravir/pmc11745048-117-0-5
Average 95 stars, based on 1 article reviews
molnupiravir mpv - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
eidd 2749  (MedChemExpress)
94
MedChemExpress eidd 2749
(A–E) Dose-response curves are shown for various small-molecule inhibitors against rGhV M-GS* (purple) and rNiV (orange). CHO-B2 cells were infected at an MOI of 0.05 and treated with (A) <t>EIDD-2749,</t> (B) GHP-88309, (C) remdesivir, (D) EIDD-1931 (molnupiravir active form), or (E) favipiravir (T-705). (F and G) Additional dose-response curves were measured in primary human astrocytes for (F) EIDD-2749 and (G) GHP-88309 under the same MOI and assay conditions. (H) Summary of half-maximal inhibitory concentrations (IC 50 ) derived from the dose-response curves in (A–G). Each row indicates the respective compound, virus, calculated IC 50 , corresponding 95% confidence interval, and the cell type in which the assay was performed. IC 50 values were determined in GraphPad Prism by nonlinear regression of (inhibitor) vs. normalized response. All experiments were conducted in biological triplicate. Error bars depict standard deviation.
Eidd 2749, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/eidd/EIDD-2749/pmc13107972-20-0-3
Average 94 stars, based on 1 article reviews
eidd 2749 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
eidd  (BOC Sciences)
93
BOC Sciences eidd
(A–E) Dose-response curves are shown for various small-molecule inhibitors against rGhV M-GS* (purple) and rNiV (orange). CHO-B2 cells were infected at an MOI of 0.05 and treated with (A) <t>EIDD-2749,</t> (B) GHP-88309, (C) remdesivir, (D) EIDD-1931 (molnupiravir active form), or (E) favipiravir (T-705). (F and G) Additional dose-response curves were measured in primary human astrocytes for (F) EIDD-2749 and (G) GHP-88309 under the same MOI and assay conditions. (H) Summary of half-maximal inhibitory concentrations (IC 50 ) derived from the dose-response curves in (A–G). Each row indicates the respective compound, virus, calculated IC 50 , corresponding 95% confidence interval, and the cell type in which the assay was performed. IC 50 values were determined in GraphPad Prism by nonlinear regression of (inhibitor) vs. normalized response. All experiments were conducted in biological triplicate. Error bars depict standard deviation.
Eidd, supplied by BOC Sciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/eidd/EIDD-2801/pm40379030-85-10-38
Average 93 stars, based on 1 article reviews
eidd - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
eidd-2801  (BioTherapeutics Inc)
90
BioTherapeutics Inc eidd-2801
(A–E) Dose-response curves are shown for various small-molecule inhibitors against rGhV M-GS* (purple) and rNiV (orange). CHO-B2 cells were infected at an MOI of 0.05 and treated with (A) <t>EIDD-2749,</t> (B) GHP-88309, (C) remdesivir, (D) EIDD-1931 (molnupiravir active form), or (E) favipiravir (T-705). (F and G) Additional dose-response curves were measured in primary human astrocytes for (F) EIDD-2749 and (G) GHP-88309 under the same MOI and assay conditions. (H) Summary of half-maximal inhibitory concentrations (IC 50 ) derived from the dose-response curves in (A–G). Each row indicates the respective compound, virus, calculated IC 50 , corresponding 95% confidence interval, and the cell type in which the assay was performed. IC 50 values were determined in GraphPad Prism by nonlinear regression of (inhibitor) vs. normalized response. All experiments were conducted in biological triplicate. Error bars depict standard deviation.
Eidd 2801, supplied by BioTherapeutics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/eidd/eidd+2801/10__1021_slash_acs__orglett__0c03052-165-16-12
Average 90 stars, based on 1 article reviews
eidd-2801 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
phase 2 eidd-4801 efficacy trials  (BioTherapeutics Inc)
90
BioTherapeutics Inc phase 2 eidd-4801 efficacy trials
(A–E) Dose-response curves are shown for various small-molecule inhibitors against rGhV M-GS* (purple) and rNiV (orange). CHO-B2 cells were infected at an MOI of 0.05 and treated with (A) <t>EIDD-2749,</t> (B) GHP-88309, (C) remdesivir, (D) EIDD-1931 (molnupiravir active form), or (E) favipiravir (T-705). (F and G) Additional dose-response curves were measured in primary human astrocytes for (F) EIDD-2749 and (G) GHP-88309 under the same MOI and assay conditions. (H) Summary of half-maximal inhibitory concentrations (IC 50 ) derived from the dose-response curves in (A–G). Each row indicates the respective compound, virus, calculated IC 50 , corresponding 95% confidence interval, and the cell type in which the assay was performed. IC 50 values were determined in GraphPad Prism by nonlinear regression of (inhibitor) vs. normalized response. All experiments were conducted in biological triplicate. Error bars depict standard deviation.
Phase 2 Eidd 4801 Efficacy Trials, supplied by BioTherapeutics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/eidd/phase+2+eidd+4801+efficacy+trials/pm35023215-134-7-4
Average 90 stars, based on 1 article reviews
phase 2 eidd-4801 efficacy trials - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
eidd-1931 (5 µm -100 µm)  (Promega)
90
Promega eidd-1931 (5 µm -100 µm)
(A). Vero cells were treated with 5’-FU and <t>EIDD-1931</t> at indicated concentrations. At 48 hr post treatment, cell viability was measured using CellTiter-Glo Viability Assay (Promega). Data shown are the average (n=4) and SEM. (B) and (C). Vero cells were treated with 5-FU and EIDD-1931 at different concentrations as indicated. Cells were infected with wt rLASV (wt) and ExoN-rLASV (ExoN-) at MOI 0.1. At 48 hpi, virus titers were determined by plaque assay. Log10 virus titer changes relative to the virus titer of non-treated cells are shown. Data presented are the mean and the SEM of three independent experiments.
Eidd 1931 (5 µm 100 µm), supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/eidd/eidd+1931++5+%C2%B5m++100+%C2%B5m+/bio_rxiv__2023__04__12__536665-135-5-22
Average 90 stars, based on 1 article reviews
eidd-1931 (5 µm -100 µm) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
eidd-1931  (Jubilant Biosys Ltd)
90
Jubilant Biosys Ltd eidd-1931
(A). Vero cells were treated with 5’-FU and <t>EIDD-1931</t> at indicated concentrations. At 48 hr post treatment, cell viability was measured using CellTiter-Glo Viability Assay (Promega). Data shown are the average (n=4) and SEM. (B) and (C). Vero cells were treated with 5-FU and EIDD-1931 at different concentrations as indicated. Cells were infected with wt rLASV (wt) and ExoN-rLASV (ExoN-) at MOI 0.1. At 48 hpi, virus titers were determined by plaque assay. Log10 virus titer changes relative to the virus titer of non-treated cells are shown. Data presented are the mean and the SEM of three independent experiments.
Eidd 1931, supplied by Jubilant Biosys Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/eidd/eidd+1931/pm39955340-209-0-4
Average 90 stars, based on 1 article reviews
eidd-1931 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
eidd-1931  (MedKoo Inc)
90
MedKoo Inc eidd-1931
(A). Vero cells were treated with 5’-FU and <t>EIDD-1931</t> at indicated concentrations. At 48 hr post treatment, cell viability was measured using CellTiter-Glo Viability Assay (Promega). Data shown are the average (n=4) and SEM. (B) and (C). Vero cells were treated with 5-FU and EIDD-1931 at different concentrations as indicated. Cells were infected with wt rLASV (wt) and ExoN-rLASV (ExoN-) at MOI 0.1. At 48 hpi, virus titers were determined by plaque assay. Log10 virus titer changes relative to the virus titer of non-treated cells are shown. Data presented are the mean and the SEM of three independent experiments.
Eidd 1931, supplied by MedKoo Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/eidd/eidd+1931/pmc10224493-60-0-4
Average 90 stars, based on 1 article reviews
eidd-1931 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
eidd-1931  (Immunic AG)
90
Immunic AG eidd-1931
(A). Vero cells were treated with 5’-FU and <t>EIDD-1931</t> at indicated concentrations. At 48 hr post treatment, cell viability was measured using CellTiter-Glo Viability Assay (Promega). Data shown are the average (n=4) and SEM. (B) and (C). Vero cells were treated with 5-FU and EIDD-1931 at different concentrations as indicated. Cells were infected with wt rLASV (wt) and ExoN-rLASV (ExoN-) at MOI 0.1. At 48 hpi, virus titers were determined by plaque assay. Log10 virus titer changes relative to the virus titer of non-treated cells are shown. Data presented are the mean and the SEM of three independent experiments.
Eidd 1931, supplied by Immunic AG, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/eidd/eidd+1931/pmc09866877-44-0-5
Average 90 stars, based on 1 article reviews
eidd-1931 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
eidd-1931  (BioTherapeutics Inc)
90
BioTherapeutics Inc eidd-1931
(A). Vero cells were treated with 5’-FU and <t>EIDD-1931</t> at indicated concentrations. At 48 hr post treatment, cell viability was measured using CellTiter-Glo Viability Assay (Promega). Data shown are the average (n=4) and SEM. (B) and (C). Vero cells were treated with 5-FU and EIDD-1931 at different concentrations as indicated. Cells were infected with wt rLASV (wt) and ExoN-rLASV (ExoN-) at MOI 0.1. At 48 hpi, virus titers were determined by plaque assay. Log10 virus titer changes relative to the virus titer of non-treated cells are shown. Data presented are the mean and the SEM of three independent experiments.
Eidd 1931, supplied by BioTherapeutics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/eidd/eidd+1931/us11896648-1753-13-15
Average 90 stars, based on 1 article reviews
eidd-1931 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


(A–E) Dose-response curves are shown for various small-molecule inhibitors against rGhV M-GS* (purple) and rNiV (orange). CHO-B2 cells were infected at an MOI of 0.05 and treated with (A) EIDD-2749, (B) GHP-88309, (C) remdesivir, (D) EIDD-1931 (molnupiravir active form), or (E) favipiravir (T-705). (F and G) Additional dose-response curves were measured in primary human astrocytes for (F) EIDD-2749 and (G) GHP-88309 under the same MOI and assay conditions. (H) Summary of half-maximal inhibitory concentrations (IC 50 ) derived from the dose-response curves in (A–G). Each row indicates the respective compound, virus, calculated IC 50 , corresponding 95% confidence interval, and the cell type in which the assay was performed. IC 50 values were determined in GraphPad Prism by nonlinear regression of (inhibitor) vs. normalized response. All experiments were conducted in biological triplicate. Error bars depict standard deviation.

Journal: Cell reports

Article Title: De novo recovery of Ghana virus, an African bat Henipavirus, reveals differential tropism and attenuated pathogenicity compared to Nipah virus

doi: 10.1016/j.celrep.2026.117074

Figure Lengend Snippet: (A–E) Dose-response curves are shown for various small-molecule inhibitors against rGhV M-GS* (purple) and rNiV (orange). CHO-B2 cells were infected at an MOI of 0.05 and treated with (A) EIDD-2749, (B) GHP-88309, (C) remdesivir, (D) EIDD-1931 (molnupiravir active form), or (E) favipiravir (T-705). (F and G) Additional dose-response curves were measured in primary human astrocytes for (F) EIDD-2749 and (G) GHP-88309 under the same MOI and assay conditions. (H) Summary of half-maximal inhibitory concentrations (IC 50 ) derived from the dose-response curves in (A–G). Each row indicates the respective compound, virus, calculated IC 50 , corresponding 95% confidence interval, and the cell type in which the assay was performed. IC 50 values were determined in GraphPad Prism by nonlinear regression of (inhibitor) vs. normalized response. All experiments were conducted in biological triplicate. Error bars depict standard deviation.

Article Snippet: EIDD-2749 (4′-Fluorouridine) , MedChemExpress , Cat# HY-146246.

Techniques: Infection, Derivative Assay, Virus, Standard Deviation

(A). Vero cells were treated with 5’-FU and EIDD-1931 at indicated concentrations. At 48 hr post treatment, cell viability was measured using CellTiter-Glo Viability Assay (Promega). Data shown are the average (n=4) and SEM. (B) and (C). Vero cells were treated with 5-FU and EIDD-1931 at different concentrations as indicated. Cells were infected with wt rLASV (wt) and ExoN-rLASV (ExoN-) at MOI 0.1. At 48 hpi, virus titers were determined by plaque assay. Log10 virus titer changes relative to the virus titer of non-treated cells are shown. Data presented are the mean and the SEM of three independent experiments.

Journal: bioRxiv

Article Title: Lassa virus NP DEDDh 3’-5’ exoribonuclease activity is required for optimal viral RNA replication

doi: 10.1101/2023.04.12.536665

Figure Lengend Snippet: (A). Vero cells were treated with 5’-FU and EIDD-1931 at indicated concentrations. At 48 hr post treatment, cell viability was measured using CellTiter-Glo Viability Assay (Promega). Data shown are the average (n=4) and SEM. (B) and (C). Vero cells were treated with 5-FU and EIDD-1931 at different concentrations as indicated. Cells were infected with wt rLASV (wt) and ExoN-rLASV (ExoN-) at MOI 0.1. At 48 hpi, virus titers were determined by plaque assay. Log10 virus titer changes relative to the virus titer of non-treated cells are shown. Data presented are the mean and the SEM of three independent experiments.

Article Snippet: Treatment of Vero cells with EIDD-1931 (5 µM -100 µM) alone did not substantially affect cell viability ( , CellTiter-Glo Viability Assay, Promega).

Techniques: Viability Assay, Infection, Virus, Plaque Assay